Liver Tumor
Conditions
Keywords
liver tumor, Two stage hepatectomy, Hypertrophy, laparoscopy, ALPPS
Brief summary
The purpose of this research is evaluate the results with laparoscopic ALPPS procedure in a single center. The validity, feasibility and limitations were assessed objectively through our clinical prospective study.The investigators expect laparoscopic ALPPS is safe, effective and feasible.
Detailed description
Background: Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) is a breakthrough in the field of hepatobiliary surgery in recent years，which stimulates the remnant liver volume(RLV) grew by 74%-87.2% in 9 to 13 days。The published literature reported that the two stages of ALPPS are the conventional laparotomy surgery，Patients need to undergo the injury of two open operations in a short time. The incidence of postoperative complications and mortality rate is as high as 53% -73% and 12%-27%.The aim of this study was to evaluate the results with laparoscopic ALPPS procedure in a single center, with special emphasis in validity, feasibility and limitations. Results: Clinical data include: operation time, intraoperative blood loss, volume of blood transfusion, complications and mortality, postoperative liver function, long-term curative effect and survival time were collected and analysed. Statistical method:groups t-test ，univariate/multivariate analysis, logistic regression analysis, mixed linear regression, Cox survival analysis ，Kaplan-Meier survival analysis，Log-rank survival curves were used.
Interventions
PROCEDURELaparoscopic ALPPS
Laparoscopic Associating Liver Partition and Portal Vein Ligation for Two-stage Hepatectomy
Sponsors
Shuguo Zheng, MD
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Patients with marginally resectable or primarily non-resectable locally advanced liver tumors * Insufficient future liver remnant (FLR) either in volume or quality
Exclusion criteria
* Unresectable liver metastases in the future liver remnant or unresectable extrahepatic metastases * Severe portal hypertension * High anesthesiological risk * Unresectable primary tumor
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety of the procedure defined as the incidence of postoperative complications and mortality | within the first 90 days after the first stage |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| survival rate | 3 years | follow-up after the surgery every 3months, to understand relapse, death, statistics 1-year, 3-year overall survival rates，disease-free survival rates , recurrence and metastasis rate. |
Countries
China
Contacts
Primary ContactShuguo Zheng
Outcome results
None listed